

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/097061 A1

(51) International Patent Classification:

A61P 35/02 (2006.01) C07K 16/28 (2006.01)
C07K 14/00 (2006.01) C07K 16/40 (2006.01)

(21) International Application Number:

PCT/IB2021/060216

(22) International Filing Date:

04 November 2021 (04.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/110,490 06 November 2020 (06.11.2020) US
63/110,501 06 November 2020 (06.11.2020) US
63/114,370 16 November 2020 (16.11.2020) US
63/114,371 16 November 2020 (16.11.2020) US
63/147,488 09 February 2021 (09.02.2021) US
63/147,501 09 February 2021 (09.02.2021) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **AARDALEN, Kimberly Marie**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **CEBE, Regis**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **CHELUR, Dattananda**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **DRANOFF, Glenn**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GRANDA, Brian Walter**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HASSOUNAH, Nadia**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HONG, Connie**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **JANG, Sunyoung**; 263 Harvard Street, #8, Cambridge, Massachusetts 02139 (US). **LU, Haihui**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **RAYO, Amy**; c/o Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SKEGRO, Darko**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **WOO, Janghee**; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES

(57) Abstract: The present disclosure provides combinations of anti-CD19 agents and B cell targeting agents and methods of treating subjects having B cell malignancies with combinations of anti-CD19 agents and a B cell targeting agents.

WO 2022/097061 A1